Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-132872 · Präparat HOS-097310
13 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration Dexamethasone, Potential ↑in plasma concentrations of Careful monitoring. fluticasone, these drugs Dose adjustment of these medicinal methylprednisolone products may be required. Lipid Lowering Drugs Lovastatin, simvastatin, Potential ↑in plasma concentrations of Contraindicated due to an increased atorvastatin* these drugs risk of skeletal muscle toxicity, including rhabdomyolysis (see section 4.3). Respiratory Drugs Salmeterol Salmeterol Not recommended due to an AUC: ↑ 15-fold increased risk in QT prolongation. Cmax: ↑ 1.4-fold Urological Drugs Fesoterodine Fesoterodine active metabolite: Not recommended due to an Tolterodine AUC: ↑ 2.3-fold increased risk of QT prolongation. Solifenacin Cmax: ↑ 2.0-fold Fesoterodine and solifenacin are contraindicated in patients with renal Solifenacin: impairment (see section 4.3). AUC: ↑ 3.0-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): solifenacin (HOS-116433) tolterodine (HOS-087792) fluticasone (HOS-108914) lovastatin (HOS-086157) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) simvastatin (HOS-086158) salmeterol (HOS-086285) dexamethasone (HOS-084535) fesoterodine (HOS-116432)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage c1a5069997a87321e46bd8aff4444df27aef883235aeff401c7a8ea1faec7fc9 · Zeichen 27524–29247 im Abschnitt